

Patisiran (Onpattro®)

Reduce direct handling to a minimum and wear appropriate personal protective equipment.		
Patisiran dosing is weight based; ensure accuracy of documented weight before administration		
Caution High Administration Risk rating		
Form & Storage	2mg/mL concentrate for solution for infusion Each 5mL vial contains patisiran sodium equivalent to 10 mg patisiran formulated as lipid nanoparticles.	Store in a refrigerator (2°C – 8°C). Do not freeze. Keep the vial in the outer carton in order to protect from light
Reconstitution	Already in solution MUST be further diluted before administration Do NOT shake	
Compatibility & Stability	Sodium chloride 0.9% Inspect visually for particulate matter and discolouration. Do not use if discolouration or foreign particles are present. Onpattro is a white to off-white, opalescent, homogeneous solution.	
Premedication	Each of the following medicinal products should be given on the day of Onpattro infusion at least 60 minutes prior to the start of infusion: • Dexamethasone 10 mg IV stat (Consider switch to 10mg PO from 3rd infusion if previous infusions tolerated) • Chlorphenamine 10mg IV stat (Consider switch to 4mg PO from 3rd infusion if previous infusions tolerated) • Paracetamol 500mg -1g PO stat • Famotidine 20mg PO stat	
Administration	IV Infusion • Calculate the required volume of Onpattro based on the recommended weight-based dosage • Withdraw the entire contents of one or more vials into a single sterile syringe. • Filter Onpattro through a sterile 0.45 micron polyethersulfone (PES) syringe filter into a sterile syringe. • Withdraw the required volume of filtered Onpattro from the sterile container using a sterile syringe. • Remove 50mL + calculated volume of Onpattro from a 250mL bag sodium chloride 0.9%. Dilute the required volume of filtered Onpattro into this infusion bag containing sodium chloride 0.9% for a total volume of 200 mL. • Use infusion bags that are free of di(2-ethylhexyl)phthalate (DEHP). • Gently invert the bag to mix the solution. • Do not shake. Do not mix or dilute with other medicinal products. • A dedicated line with an infusion set containing a 1.2 micron polyethersulfone (PES) in-line infusion filter must be used. The infusion sets and lines must be free of di(2-ethylhexyl)phthalate (DEHP)	

*This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications.
Further information is available from Pharmacy on 22146 or 22542*

	- The diluted solution of Onpattro should be infused intravenously over approximately 80 minutes Initial infusion rate of approximately 1 mL/min for the first 15 minutes Followed by an increase to approximately 3 mL/min for the remainder of the infusion. The duration of the infusion may be extended in the event of an IRR
Monitoring	Pre and post vital signs
Documentation Requirements	Document batch numbers and expiry dates of vials in medical notes.
Adverse Drug Reactions	Commonly reported adverse effects with patisiran include upper respiratory-tract infections, dyspepsia, muscle spasm, bronchitis, vertigo, and peripheral oedema
Additional Information	Vitamin A supplementation at approximately 2 500 IU vitamin A per day is advised for patients treated with Onpattro to reduce the potential risk of ocular toxicity due to vitamin A deficiency. Referral for ophthalmological assessment is recommended if patients develop ocular symptoms suggestive of vitamin A deficiency, including reduced night vision or night blindness, persistent dry eyes, eye inflammation, corneal inflammation or ulceration, corneal thickening or corneal perforation - Particular care should be taken by women of child-bearing potential and during early stages of pregnancy as levels of serum vitamin A too low or too high may increase the risk of fetal malformations. - Onpattro is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy. - See PPG-CUH-CUH-243 <u>Policy Procedure and Guidelines for Management of Patients Attending CUH Infusion Unit for Intravenous Therapy CUH</u> for more information

Information provided relates to Onpattro® (Alnylam)